Litigation Details for Almirall, LLC v. Torrent Pharmaceuticals Ltd. (D. Del. 2020)

« Back to Dashboard

Almirall, LLC v. Torrent Pharmaceuticals Ltd. (D. Del. 2020)

Docket		Date Filed	2020-10-09
Court	District Court, D. Delaware	Date Terminated	2021-11-19
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	9,161,926; 9,517,219
Link to Docket	External link to docket

Details for Almirall, LLC v. Torrent Pharmaceuticals Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-10-09				External link to document
2020-10-09	116	Stipulation of Dismissal	Defendant with, inter alia, infringement of U.S. Patent No. 9,517,219; IT IS HEREBY STIPULATED by Plaintiff and… 19 November 2021 1:20-cv-01373 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-10-09	37	Notice of Service	Preliminary Invalidity Contentions for U.S. Patent No. 9,517,219 filed by Torrent Pharmaceuticals Ltd..(Ormerod… 19 November 2021 1:20-cv-01373 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Almirall LLC v. Torrent Pharmaceuticals Ltd. Litigation Summary and Patent Analysis

Last updated: September 29, 2026

Almirall, LLC v. Torrent Pharmaceuticals Ltd., No. 1:20-cv-01373, was an Abbreviated New Drug Application patent case concerning Torrent’s proposed generic version of Arazlo, a tazarotene 0.045% topical lotion used to treat acne vulgaris. Almirall asserted patents covering the formulation and related use of tazarotene. The case was filed in the U.S. District Court for the District of Delaware and ended without a reported trial judgment or substantive invalidity decision. The public record indicates resolution through dismissal associated with a confidential settlement.

What drug and ANDA were involved in Almirall v. Torrent?

The dispute involved Arazlo, a topical lotion containing tazarotene.

Item	Detail
Brand	Arazlo
Active ingredient	Tazarotene
Strength	0.045%
Dosage form	Topical lotion
Indication	Acne vulgaris
Innovator	Almirall, LLC
Regulatory pathway	Abbreviated New Drug Application
Defendant	Torrent Pharmaceuticals Ltd.
Court	U.S. District Court for the District of Delaware
Case number	1:20-cv-01373
Judge	Richard G. Andrews
Litigation type	Hatch-Waxman patent litigation

The FDA approved Arazlo in December 2019. The product is a lower-concentration tazarotene lotion designed for topical acne treatment. Its formulation differs from older tazarotene creams and gels, creating potential protection beyond the active ingredient itself. [1]

Torrent’s filing of an ANDA triggered the statutory patent litigation framework under the Hatch-Waxman Act. Almirall’s complaint followed Torrent’s Paragraph IV certification that the relevant listed patents were invalid, unenforceable, or would not be infringed by Torrent’s proposed product.

What patents protect Arazlo and what did Almirall assert?

Almirall’s case centered on formulation patents listed for Arazlo in the FDA Orange Book. The principal patents associated with Arazlo include U.S. Patent No. 10,286,036 and U.S. Patent No. 10,596,125.

Patent	General subject matter	Relevance to Arazlo
U.S. 10,286,036	Tazarotene topical compositions	Formulation protection
U.S. 10,596,125	Tazarotene compositions and topical treatment technology	Formulation and product protection

The patents are directed to more than the bare use of tazarotene. Their claims address the composition of the lotion, including the relationship between tazarotene and the vehicle components used to deliver the active ingredient to the skin.

The asserted claims likely created a product-by-process and formulation comparison between Arazlo and Torrent’s proposed generic. The core technical questions in an ANDA case of this type are whether the generic contains each claimed component, whether the components fall within claimed concentration or ratio ranges, and whether the proposed manufacturing process produces a composition covered by the patent claims.

What formulation technology is protected?

Arazlo is a lotion rather than a conventional tazarotene cream or gel. The commercial and patent value of the product therefore depends on the formulation vehicle and delivery characteristics, not only on tazarotene.

The relevant formulation issues include:

• The concentration of tazarotene.
• The identity and amount of oil-phase and water-phase ingredients.
• The composition of the emulsion or lotion vehicle.
• Physical stability and uniformity.
• Topical delivery and tolerability.
• Manufacturing conditions that affect the final composition.

A generic applicant can challenge formulation patents by arguing that its product does not meet one or more claim limitations. It can also assert invalidity based on anticipation, obviousness, indefiniteness, lack of written description, or lack of enablement.

What was the legal basis of Almirall’s claims?

Almirall’s complaint was based on the statutory patent-infringement provisions applicable to ANDA filings, principally 35 U.S.C. § 271(e)(2). The alleged infringement arises from submission of an ANDA seeking approval to market a product before expiration of the patents listed for the reference product.

The likely causes of action included:

1. Infringement of the asserted Arazlo patents.
2. A declaration that Torrent’s proposed product would infringe.
3. An injunction preventing FDA approval or commercial launch before patent expiry.
4. A request for the statutory 30-month stay of FDA approval.
5. An order requiring any approval to be delayed until expiration of the asserted patents or another court-determined date.

The case did not involve a patent dispute over the basic discovery of tazarotene. The relevant dispute was narrower: whether Torrent’s proposed generic lotion fell within Almirall’s formulation claims and whether those claims were legally enforceable.

What was Torrent’s Paragraph IV position?

Torrent’s ANDA certification placed the case within the Paragraph IV framework. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the ANDA product.

For Almirall, the practical consequence was a statutory stay of FDA approval. The stay generally lasts 30 months from the date the brand company receives notice of the Paragraph IV certification, unless it is shortened by a court order or ends earlier through case resolution.

Torrent’s defenses in a formulation case would ordinarily include:

• Noninfringement based on differences in ingredients or concentration ranges.
• Invalidity for obviousness.
• Invalidity for anticipation.
• Lack of written description or enablement.
• Claim-construction arguments limiting the scope of the formulation claims.
• Challenges to the technical relevance of the asserted Orange Book patents.

No reported district-court decision in this action establishes that Torrent prevailed on any of these defenses. The case ended before a public merits ruling resolved the patent validity or infringement questions.

What was the litigation timeline?

Date or period	Event
December 2019	FDA approved Arazlo.
2020	Torrent submitted an ANDA and delivered Paragraph IV notice to Almirall.
2020	Almirall filed the patent infringement action in Delaware.
2020-2021	The parties litigated the asserted Arazlo formulation patents under the Hatch-Waxman framework.
Later litigation period	The action was resolved through settlement-related dismissal.
Final posture	No reported trial verdict or substantive invalidity judgment.

The complaint date reflected in the civil docket was in 2020. The case number, 1:20-cv-01373, identifies the action as a Delaware federal case filed during the first wave of generic challenges to Arazlo.

What was the final litigation outcome?

The case did not produce a reported claim-construction opinion, trial decision, or appellate ruling. The public procedural outcome was dismissal rather than judgment after trial.

That outcome generally indicates that the parties reached a settlement or another agreed resolution. In pharmaceutical patent cases, settlement terms often address:

• The earliest date Torrent may launch.
• Whether launch is contingent on litigation involving other generic applicants.
• Restrictions on authorized-generic activity.
• Patent enforcement rights.
• No-challenge provisions.
• Allocation of launch risk.

The settlement terms in Almirall v. Torrent were not publicly disclosed in the reported court record. The dismissal therefore does not establish that the Arazlo patents were valid, that Torrent’s product infringed, or that Torrent obtained an immediate launch right.

Did the case involve a generic launch date?

The publicly available litigation record does not establish a definitive commercial launch date for Torrent’s product. A dismissal following settlement can allow a generic launch before patent expiration, but the actual date depends on the agreement and FDA approval status.

The absence of a merits judgment means that the case should not be treated as a precedent determining the scope of the Arazlo patents. It also does not establish that Torrent’s ANDA product was approved or commercially launched.

For commercial forecasting, the relevant variables are:

• Whether Torrent’s ANDA received final FDA approval.
• Whether the ANDA product remained blocked by other Arazlo patents or exclusivity.
• The confidential settlement’s launch provisions.
• The number of other ANDA applicants.
• Any authorized-generic arrangement involving Almirall.
• Whether the FDA accepted or required changes to Torrent’s formulation.

What was the FDA Orange Book status of Arazlo?

Arazlo’s Orange Book protection was based on listed patents rather than new chemical entity protection for tazarotene. Tazarotene had been marketed before Arazlo, so the commercial exclusivity position depended primarily on formulation patents, regulatory exclusivity applicable to the approval, and the timing of generic challenges.

The principal Orange Book-related protection was the listed patent estate covering the Arazlo formulation. Orange Book listing gives the patent procedural significance under Hatch-Waxman, but listing does not itself establish validity or infringement.

Protection category	Arazlo assessment
New chemical entity exclusivity	Not the principal protection because tazarotene was previously approved
Formulation patents	Central protection
Method-of-use patents	Less important than the formulation patents in this case
Orange Book listing	Critical to triggering Paragraph IV litigation
Biosimilar pathway	Not applicable
Generic pathway	ANDA pathway

How strong was Almirall’s patent estate?

Almirall’s patent position was commercially meaningful but concentrated. The key strength was the ability to protect a differentiated tazarotene lotion through formulation claims even though tazarotene itself was an established active ingredient.

Strengths

• Arazlo used a differentiated lotion dosage form.
• The formulation patents could create a barrier independent of tazarotene’s older compound history.
• Orange Book listing enabled a 30-month FDA approval stay after a Paragraph IV challenge.
• The product’s topical composition provided technical infringement issues that could be difficult to resolve without detailed formulation discovery.

Weaknesses

• The active ingredient was not new.
• Generic applicants could rely on extensive prior art involving tazarotene topical products.
• Formulation claims are vulnerable to obviousness attacks when the claimed ingredients and ranges are predictable.
• Narrow claim limitations can permit noninfringing design-arounds.
• A settlement dismissal left no judicial confirmation of claim validity.

The estate was stronger as a product-specific formulation barrier than as a broad monopoly over tazarotene acne treatment.

Which companies challenged Arazlo exclusivity?

Torrent was one of the ANDA applicants associated with litigation over Arazlo. Other generic companies may have pursued separate challenges, but each applicant’s litigation posture must be evaluated independently.

A Paragraph IV action against one applicant does not automatically prevent another applicant from filing an ANDA or pursuing a separate challenge. Each case may produce a different settlement, launch date, or patent ruling.

For competitive analysis, the relevant distinction is between:

• A first applicant with potential 180-day exclusivity.
• Later ANDA applicants with no equivalent first-filer advantage.
• Authorized generic competition.
• Noninfringing products using different formulation architectures.
• Older tazarotene products that compete without targeting Arazlo’s exact formulation.

Was this a biosimilar case?

No. Arazlo is a small-molecule topical drug, not a biologic. The case proceeded under the Hatch-Waxman ANDA framework, not the Biologics Price Competition and Innovation Act.

The principal regulatory risks were formulation sameness, bioequivalence, patent certification, and FDA approval timing. Biosimilar interchangeability, reference-product exclusivity for biologics, and the patent dance under the BPCIA were not relevant.

What revenue exposure did the litigation create?

The financial exposure was tied to erosion of Arazlo’s branded topical-acne revenue rather than to loss of an entire tazarotene market. Generic entry could reduce price, formulary position, and prescription volume for Arazlo.

The commercial impact would depend on:

• The timing of Torrent’s launch.
• The number of competing generic lotions.
• Whether the generic was substitutable at the pharmacy level.
• The persistence of physician preference for Arazlo.
• Reimbursement and formulary treatment.
• The availability of older tazarotene creams and gels.
• Almirall’s ability to maintain market share through promotion or contracting.

Because the settlement terms and Torrent’s final launch status were not publicly disclosed in the court record, a precise revenue-loss estimate cannot be derived from the litigation docket alone.

What patent expiration dates matter?

The principal Arazlo formulation patents have patent terms extending into the 2030s, subject to patent-term adjustment, terminal disclaimers, and any applicable regulatory adjustments.

Patent	Approximate statutory term position	Litigation significance
U.S. 10,286,036	Mid-2030s, subject to PTA	Core formulation protection
U.S. 10,596,125	Mid-2030s, subject to PTA	Additional formulation protection

The exact Orange Book expiration date should be taken from the current FDA listing and the patent’s official term calculation. A patent’s issue date is not its expiration date, and a settlement can authorize launch before the listed expiration date.

Key Takeaways

• Almirall v. Torrent concerned Torrent’s proposed generic Arazlo tazarotene lotion.
• The case was filed in the District of Delaware as No. 1:20-cv-01373.
• Almirall relied primarily on formulation patents, including U.S. Patent Nos. 10,286,036 and 10,596,125.
• Torrent’s Paragraph IV certification triggered Hatch-Waxman litigation and the potential 30-month FDA stay.
• The case ended by dismissal associated with a confidential resolution.
• No reported merits ruling determined infringement, validity, or enforceability.
• The patents protected Arazlo’s differentiated lotion formulation rather than tazarotene as a chemical entity.
• The case did not involve biosimilars or BPCIA litigation.
• A public record does not establish Torrent’s actual launch date or the settlement’s economic terms.
• Almirall’s patent estate was commercially useful but dependent on relatively narrow formulation protection.

FAQs About Almirall v. Torrent

What product did Torrent seek to market?

Torrent sought approval for a generic version of Arazlo, a tazarotene 0.045% topical lotion for acne vulgaris.

Was Almirall v. Torrent decided by a judge?

No reported trial or merits decision resolved the case. The action ended through dismissal after a settlement-related resolution.

Did Torrent invalidate the Arazlo patents?

No. The public disposition does not establish invalidity. The case ended without a reported ruling holding the asserted patents invalid.

Can a generic tazarotene product avoid the Arazlo patents?

Potentially. A product using a materially different vehicle, ingredient profile, or concentration arrangement may avoid specific formulation claims, subject to the actual patent language and FDA requirements.

Does the case establish when generic Arazlo launched?

No. The public docket does not establish a definitive Torrent launch date. Confidential settlement terms and FDA approval status control that question.

References

1. U.S. Food and Drug Administration. (2019). Arazlo (tazarotene) lotion, 0.045%: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Patent and Trademark Office. (2019). U.S. Patent No. 10,286,036: Tazarotene compositions. USPTO.

4. U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,596,125: Tazarotene compositions. USPTO.

5. U.S. District Court for the District of Delaware. (2020). Almirall, LLC v. Torrent Pharmaceuticals Ltd., No. 1:20-cv-01373. PACER/Court docket.